Semaglutide and tirzepatide are the two most widely prescribed injectable peptides for weight management. Both belong to the incretin-based therapy class and have demonstrated strong efficacy in large-scale clinical trials. But they differ in mechanism, potency, and clinical profile. This article breaks down what the research actually shows so you can have a more informed conversation with your healthcare provider.
How they work
Semaglutide (marketed as Wegovy for weight management and Ozempic for type 2 diabetes) is a GLP-1 receptor agonist. It mimics the naturally occurring hormone glucagon-like peptide-1, which slows gastric emptying, reduces appetite, and enhances insulin secretion in response to food.
Tirzepatide (marketed as Zepbound for weight management and Mounjaro for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism is thought to produce additive effects on appetite suppression, insulin sensitivity, and fat metabolism.
Key distinction: Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GIP and GLP-1). This dual-agonist approach is the primary reason tirzepatide tends to produce greater weight loss in clinical trials.
Clinical trial results
Semaglutide: the STEP trials
The STEP (Semaglutide Treatment Effect in People with obesity) program is the landmark trial series for semaglutide 2.4 mg. In STEP 1, participants without type 2 diabetes lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. Roughly 69-79% of participants achieved at least 10% weight loss, and 51-64% achieved at least 15%.
STEP 3 combined semaglutide with intensive behavioral therapy and showed a mean weight reduction of 16.0% versus 5.7% with placebo. The two-year STEP 5 trial demonstrated sustained weight loss of 15.2% at 104 weeks, confirming that the effect holds over longer treatment periods.
Tirzepatide: the SURMOUNT trials
The SURMOUNT trial program evaluated tirzepatide at three doses in adults with obesity or overweight. In SURMOUNT-1, mean weight loss at 72 weeks was 16.0% on the 5 mg dose, 21.4% on 10 mg, and 22.5% on 15 mg, compared to 2.4% with placebo. About 96% of participants on the two higher doses achieved at least 5% body weight reduction.
SURMOUNT-4 examined maintenance of weight loss: participants who completed a 36-week lead-in period lost 20.9% of their body weight, and those who continued tirzepatide went on to achieve a total mean weight reduction of 25.3% from baseline by week 88.
Head-to-head comparison
SURPASS-2 was a 40-week head-to-head trial in patients with type 2 diabetes comparing tirzepatide (5, 10, and 15 mg) against semaglutide 1 mg. Tirzepatide was noninferior and superior to semaglutide for A1C reduction, and patients on tirzepatide 15 mg lost nearly twice as much weight as those on semaglutide 1 mg.
Side-by-side comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Brand names | Wegovy (weight), Ozempic (diabetes), Rybelsus (oral) | Zepbound (weight), Mounjaro (diabetes) |
| FDA approval (weight) | June 2021 | November 2023 |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Dose range | 0.25 mg titrated up to 2.4 mg | 2.5 mg titrated up to 15 mg |
| Mean weight loss (main trial) | ~14.9% at 68 weeks (STEP 1) | ~22.5% at 72 weeks (SURMOUNT-1, 15 mg) |
| Head-to-head weight loss | 13.7% at 72 weeks | 20.2% at 72 weeks |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation |
| Cardiovascular benefit | FDA-approved to reduce MACE risk in adults with CVD and overweight/obesity | Under investigation (SURPASS-CVOT) |
Side effects and safety
Both medications share a similar side-effect profile dominated by gastrointestinal symptoms. Nausea, vomiting, diarrhea, and constipation are most common during the dose-escalation period. These effects are typically mild to moderate and tend to diminish over the first few months of treatment.
Both drugs carry FDA boxed warnings regarding the risk of thyroid C-cell tumors based on rodent studies, though this has not been confirmed in humans. Pancreatitis, gallbladder events, and kidney injury have been reported rarely with both agents.
Which one is right for you?
If maximum weight loss is the primary goal, the evidence favors tirzepatide. Head-to-head data consistently show 5-7 percentage points more weight loss with tirzepatide compared to semaglutide 2.4 mg.
If cardiovascular risk reduction matters, semaglutide currently has the stronger evidence base. Wegovy is the only GLP-1-based weight-management drug with an FDA-approved indication for reducing the risk of major adverse cardiovascular events.
Both drugs require ongoing use to maintain weight loss. Cost, insurance coverage, and tolerability should also factor into the decision.
Key takeaway: Tirzepatide delivers greater average weight loss than semaglutide in every comparison to date, but semaglutide has a longer track record and proven cardiovascular benefits. The best choice depends on your health profile, goals, and how your body responds. Work with your healthcare provider to determine which is right for you.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340. (SURMOUNT-1)
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. (SURPASS-2)
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331(1):38-48. (SURMOUNT-4)
- Garvey WT, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity. Nat Med. 2022;28(10):2083-2091. (STEP 5)
- Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.